Abstract
In the past decades a lot of investigations were focused on searching for more accurate markers of lung cancer progression. Researchers indicate that molecular markers may be useful in forecasting of treatment outcome and overall survival rate in patients with non-small cell lung cancer. The aim of our research was to create a forecasting model in order to identify patients with stage I-II of non-small cell lung cancer and dismal prognosis. Our research covered 254 patients with the early stage of non-small cell lung cancer who underwent a cure from June 2008 till December2012 inthe Department of Thoracic Surgery of Zaporizhzhia Regional Clinical Oncologic Dispensary. Surgery was performed for all patients. Adjuvant chemotherapy was performed for 101 patients. In order to carry out multivariate Cox-regression analysis, STATISTICA 6.0 (StatSoft Inc.) program was used. The most significant from 39 variables were selected (tumor size, histological form of tumor, volume of surgical intervention, volume of conducted lymph node dissection, Ki-67 expression, EGFR expression, E-cadherin expression). We propose the computer system which can forecast survival rate in patients with the early stage of non-small cell lung cancer.
Highlights
It is well-known that lung cancer is subdivided into non-small cell lung cancer (NSCLC) which makes approximately 80% - 90% from all malignant lung tumors and small cell lung cancer which makes 10% - 20% respectively
First model was calculated with all possible predictive variables and re-calculated after removing of variability with the least significant interconnection, with response variable
Morphological, genetic factors have been researched as prognostic factors for patients with NSCLC
Summary
It is well-known that lung cancer is subdivided into non-small cell lung cancer (NSCLC) which makes approximately 80% - 90% from all malignant lung tumors and small cell lung cancer which makes 10% - 20% respectively. Fundamental type of treatment for patients with the early-stage of NSCLC is surgery. In the past decades a lot of investigations were focused on searching for more accurate markers of lung cancer progression. Researchers indicate that molecular markers may be useful in forecasting of treatment outcome and overall survival rate in patients with NSCLC [4] [6]-[9]. Large number of markers are offered for patients with NSCLC but none of them shows its high significance in clinical practice [6]. Further research of molecular forecasting markers is needed. By that time their significance in routine practice is not adequate [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
